{
  "id": 15587002,
  "title": "Switzerland’s Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials",
  "url": "https://urgent.news/2026/10/19/switzerlands-nouscom-bags-120-million-to-bring-innovative-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-19T08:52:38.000Z",
  "source": {
    "name": "EU-Startups",
    "slug": "eu-startups",
    "url": "https://www.eu-startups.com/2026/10/switzerlands-nouscom-bags-e120-million-to-bring-innovative-cancer-immunotherapy-closer-to-clinical-trials/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Basel-based Nouscom, a clinical-stage, cancer interception focused BioTech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 million ($135 million) Series D financing to fund the advancement of an investigational off-the-shelf neoantigen-based cancer immunotherapy. The round was co-led by M Ventures and Revelation Partners alongside new investors…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Nouscom raises $135M in Series D for lead cancer vaccine",
        "url": "https://urgent.news/2026/10/19/nouscom-raises-135m-in-series-d-for-lead-cancer-vaccine",
        "published": "2026-10-19T06:00:32.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}